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Background: From October 2018, adalimumab biosimilars could enter the European market. However, 
some countries, such as the Netherlands, report high discounts for the originator product that 
influence biosimilar entry. Consequently, we researched European (list) prices and reimbursement 
status of originator adalimumab, before and after the entry of biosimilars, and discuss relevant policy 
measures. 
Methods: Survey distributed via email to national experts consisting of three parts: i) general 
financing/co-payment of medicines, ii) reimbursement status and prices of originator adalimumab and 
availability of biosimilars, and iii) policy measures related to the use of adalimumab. 
Results: In the 27 surveyed countries, originator adalimumab is reimbursed (fully or only partial, and 
sometimes with restrictions in use), except for Kosovo, where it is not marketed. Following 
adalimumab biosimilars, a few countries have made changes to the reimbursement status/level or 
setting where adalimumab is available. Overall, a decrease in list prices of originator adalimumab was 
seen after loss of exclusivity rights. Some countries (Bulgaria, Germany, Greece, Italy, Latvia, the 
Netherlands and Romania) reported that list prices have not changed up to May 2019, although 
confidential discounts may exist. Adalimumab biosimilars were available in 23 of the 27 surveyed 
countries. Countries adopted various approaches to leverage competition from the use of (biosimilar) 
adalimumab. In some countries, a strategy was implemented even before patent expiry (Scotland), 
while others did not report specific measures. 
Conclusion: This study documented how European countries responded differently to patent expiry of 
originator adalimumab and biosimilar market entry, with implications for pricing and reimbursement.  
